The BRAF inhibitors, vemurafenib, and dabrafenib, which were licensed in 2011 and 2013, respectively, to treat metastatic and incurable BRAF‐mutated melanomas, are the most promising of these (Chapman et al. 2011; Rebecca, Sondak, and Smalley 2012). Here, BRAF is linked to melanoma.